India’s Obesity Drug Price War Is Starting to Look Very Real
India’s obesity-drug price war is no longer a future story. It is happening now. Reuters reported on March 31 that Novo Nordisk cut prices for Ozempic and Wegovy in India again, after the patent on semaglutide expired on March 20, 2026, opening the market to cheaper local generics. That matters because India is one of … Read more